Premium
Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure
Author(s) -
Refsgaard Jens,
Thomsen Claus,
Andreasen Frederik,
Gøtzsche Ole
Publication year - 2002
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(02)00035-1
Subject(s) - carvedilol , medicine , heart failure , hyperinsulinemia , placebo , insulin resistance , cardiology , insulin , endocrinology , alternative medicine , pathology
Background Congestive heart failure (CHF) has previously been shown to be associated with insulin resistance and hyperinsulinemia. A beneficial effect of the non‐selective β ‐ blocker carvedilol has been demonstrated in patients with CHF. However, whether the drug affects the insulin sensitivity ( S i ) is unknown. Aims To investigate whether treatment with carvedilol alters the S i in patients with CHF during a prospective, double‐blinded, placebo‐controlled study. Methods and results: The patients were randomized to receive either carvedilol ( n ‐29) or matched placebo ( n ‐17). Insulin and glucose responses were measured during a 0.3 g/kg intravenous glucose tolerance test, and S i was calculated according to Bergman's Minimal Model. Baseline S i values correlated significantly with body mass index ( r ‐−0.42, P ‐0.002), plasma urate ( r ‐−0.42, P ‐0.002), plasma HDL‐cholesterol ( r ‐0.39, P ‐0.003), maximal oxygen uptake ( r ‐0.35, P ‐0.009), plasma triglycerides ( r ‐−0.34, P ‐0.01) and weight ( r ‐−0.29, P ‐0.03). During the study the insulin sensitivity was unchanged in the carvedilol group compared with placebo (2.63±1.45 to 2.38±1.64 vs. 2.81±2.36 to 2.48±1.84×10 −4 min −1 /mU1 −1 , P ‐0.83). Conclusion Additional treatment with carvedilol is neutral with regard to influence the insulin sensitivity in patients with mild to moderate CHF.